Many synthetic agonists have also been designed for PPARG2, with the most well known being the TZDs and fibrates, both used for the treatment of metabolic disorders like type 2 diabetes mellitus (T2DM). This evidence concerns the gene PPARG and type 2 diabetes mellitus.